Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nuwellis Inc (NUWE) vs TORM plc (TRMD) Price & Performance

Nuwellis IncTrade

Price performance (Past 24H)

Key statistics

Nuwellis Inc vs TORM plc — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while TORM plc trades at $40.13 (market cap $4.04B). The key difference: TORM plc is far larger — about 1836.4× Nuwellis Inc's market cap, and TORM plc pays a 11.36% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and TORM plc for 23 Days on average.

NUWETRMD
Market Cap
$2.20M$4.04B
Volume
121,5442,225,810
Sector
HealthIndustrials
52-Week High
$146.65$41.05
52-Week Low
$0.68$19.39
Typical Hold Time
26 Days23 Days
Enterprise Value
-$1.52M$4.75B
Dividend Yield
—11.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nuwellis Inc

NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.

The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.

TORM plc

TRMD trades at $38.92, down 0.33% on the day, with strong profitability metrics including 35.52% net income margin and 26.84% ROE. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI suggests mild overbought conditions. Recent earnings showed mixed results with Q2 2026 missing expectations, while analyst consensus remains unanimously bullish with 100% buy ratings. The company maintains robust cash flow generation with $710M operating cash flow projected for 2026.

TRMD presents attractive valuation with P/E of 6.4 and EV/EBITDA of 5.11, supported by strong dividend yield from upcoming $2.40 payment. Key risks include spot rate volatility in tanker markets and recent insider selling activity. The fundamental outlook remains positive given projected revenue growth to $1.8B in 2026, though investors should monitor freight rate trends and competitive pressures in the product tanker sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NUWE
40% Buy60% Sell
Avg holding period · 26 Days
TRMD
23% Buy77% Sell
Avg holding period · 23 Days

Top news

Latest headlines on both assets

About Nuwellis Inc

Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.

Read more on NUWE →

About TORM plc

TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.

Read more on TRMD →